Jakob A - Search Results

1

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.

Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: jakob a. Invest New Drugs. 2006 May;24(3):249-53. doi: 10.1007/s10637-005-3537-1. Invest New Drugs. 2006. PMID: 16133789 Clinical Trial.

2

Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.

Jakob A, Bokemeyer C, Knop S, Schupp M, Mayer F, Kanz L. Jakob A, et al. Anticancer Drugs. 2002 Apr;13(4):405-10. doi: 10.1097/00001813-200204000-00009. Anticancer Drugs. 2002. PMID: 11984086 Clinical Trial.

3

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: jakob a. Oncology. 1999;56(1):1-12. doi: 10.1159/000011923. Oncology. 1999. PMID: 9885371 Review.

4

[Late toxicity after chemotherapy of malignant testicular tumors].

Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C. Jakob A, et al. Urologe A. 1998 Nov;37(6):635-47. doi: 10.1007/s001200050227. Urologe A. 1998. PMID: 9887493 Review. German.

5

[Diagnostic criteria in polycythemia vera].

Jakob A, Kanz L. Jakob A, et al. Dtsch Med Wochenschr. 1998 Jan 2;123(1-2):30-1. Dtsch Med Wochenschr. 1998. PMID: 9465854 German. No abstract available.

6

186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma.

Knop S, Jakob A, Kanz L, Hebart H, Bares R, Dohmen B. Knop S, et al. Among authors: jakob a. Blood. 2004 Feb 1;103(3):1175. doi: 10.1182/blood-2003-10-3593. Blood. 2004. PMID: 14729658 Free article. No abstract available.

7

Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.

Bergmann L, Goebell PJ, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler MD, Steiner T, Overkamp F, Albrecht M, Guderian G, Doehn C. Bergmann L, et al. Among authors: jakob a. Onkologie. 2013;36(3):95-100. doi: 10.1159/000348522. Epub 2013 Feb 25. Onkologie. 2013. PMID: 23485996 Free article. Clinical Trial.

8

Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.

Jakob A, Zahn MO, Nusch A, Werner T, Schnell R, Frank M, Hamm N, Däßler KU, Losem C, Welslau M, Hoevel P, Potthoff K. Jakob A, et al. J Bone Oncol. 2022 Mar 3;33:100420. doi: 10.1016/j.jbo.2022.100420. eCollection 2022 Apr. J Bone Oncol. 2022. PMID: 35340302 Free PMC article.

9

Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms.

Wieshammer S, Dreyhaupt J, Müller D, Momm F, Jakob A. Wieshammer S, et al. Among authors: jakob a. Oncology. 2016;90(3):143-50. doi: 10.1159/000443505. Epub 2016 Feb 13. Oncology. 2016. PMID: 26871423 Free article.

10

Severe cold hemagglutinin disease (CHD) successfully treated with rituximab.

Engelhardt M, Jakob A, Ruter B, Trepel M, Hirsch F, Lübbert M. Engelhardt M, et al. Among authors: jakob a. Blood. 2002 Sep 1;100(5):1922-3. doi: 10.1182/blood-2002-04-1213. Blood. 2002. PMID: 12211193 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page